Morgan Stanley Maintains Overweight on Celldex Therapeutics, Raises Price Target to $46

Morgan Stanley analyst Judah Frommer maintains Celldex Therapeutics (NASDAQ:CLDX) with a Overweight and raises the price target from $40 to $46.